Conv. Plasma
Nigella Sativa
Peg.. Lambda

All casirivimab/imdevimab..
Meta analysis
Home COVID-19 treatment researchCasirivimab/imdevimabCasirivimab/i.. (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 50% Improvement Relative Risk Mortality (b) 67% Mortality (c) -2% Death/hospitalization 71% Death/hospitalization (b) 70% Recovery time 29% Recovery time (b) 29% Casirivimab/i..  Weinreich et al.  EARLY TREATMENT  RCT Is early treatment with casirivimab/imdevimab beneficial for COVID-19? RCT 4,180 patients in the USA (September 2020 - January 2021) Lower death/hosp. (p=0.001) and faster recovery (p=0.001) Weinreich et al., NEJM, May 2021 Favors casirivimab/im.. Favors control

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19

Weinreich et al., NEJM, doi:10.1056/NEJMoa2108163 (date from preprint), NCT04425629
May 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
RCT 4,057 outpatients with >=1 risk factor for severe disease, showing significantly lower combined hospitalization/death, and significantly faster recovery with treatment. Median time from onset of symptoms 3 days. NCT04425629 (history).
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron Liu, Sheward, Tatham, VanBlargan.
risk of death, 50.0% lower, RR 0.50, p = 0.45, treatment 2 of 2,091 (0.1%), control 4 of 2,089 (0.2%), NNT 1044, Table S9.
risk of death, 67.0% lower, RR 0.33, p = 0.37, treatment 1 of 1,355 (0.1%), control 3 of 1,341 (0.2%), NNT 667, 2400mg,Table S9.
risk of death, 1.6% higher, RR 1.02, p = 1.00, treatment 1 of 736 (0.1%), control 1 of 748 (0.1%), 1200mg,Table S9.
risk of death/hospitalization, 71.3% lower, RR 0.29, p < 0.001, treatment 18 of 1,355 (1.3%), control 62 of 1,341 (4.6%), NNT 30, 2400mg.
risk of death/hospitalization, 70.4% lower, RR 0.30, p = 0.002, treatment 7 of 736 (1.0%), control 24 of 748 (3.2%), NNT 44, 1200mg.
recovery time, 28.6% lower, relative time 0.71, p < 0.001, treatment 1,355, control 1,341, 2400mg.
recovery time, 28.6% lower, relative time 0.71, p < 0.001, treatment 736, control 748, 1200mg.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Weinreich et al., 21 May 2021, Randomized Controlled Trial, USA, peer-reviewed, 39 authors, study period 24 September, 2020 - 17 January, 2021, average treatment delay 3.0 days, trial NCT04425629 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCasirivimab/i..All
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
David M Weinreich, Sumathi Sivapalasingam, Thomas Norton, Shazia Ali, Haitao Gao, Rafia Bhore, Jing Xiao, Andrea T Hooper, Jennifer D Hamilton, Bret J Musser, Diana Rofail, Mohamed Hussein, Joseph Im, Dominique Y Atmodjo, Christina Perry, Cynthia Pan, Adnan Mahmood, Romana Hosain, John D Davis, Kenneth C Turner, Alina Baum, Christos A Kyratsous, Yunji Kim, Amanda Cook, Wendy Kampman, Lilia Roque-Guerrero, Gerard Acloque, Hessam Aazami, Kevin Cannon, J Abraham Simón-Campos, Joseph A Bocchini, Bari Kowal, A Thomas Dicioccio, Yuhwen Soo, Gregory P Geba, Neil Stahl, Leah Lipsich, Ned Braunstein, Gary Herman, George D Yancopoulos
New England Journal of Medicine, doi:10.1056/nejmoa2108163
BACKGROUND In the phase 1-2 portion of an adaptive trial, REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of medical visits in patients with coronavirus disease 2019 (Covid-19). REGEN-COV has activity in vitro against current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern. METHODS In the phase 3 portion of an adaptive trial, we randomly assigned outpatients with Covid-19 and risk factors for severe disease to receive various doses of intravenous REGEN-COV or placebo. Patients were followed through day 29. A prespecified hierarchical analysis was used to assess the end points of hospitalization or death and the time to resolution of symptoms. Safety was also evaluated. RESULTS Covid-19-related hospitalization or death from any cause occurred in 18 of 1355 patients in the REGEN-COV 2400-mg group (1.3%) and in 62 of 1341 patients in the placebo group who underwent randomization concurrently (4.6%) (relative risk reduction [1 minus the relative risk], 71.3%; P<0.001); these outcomes occurred in 7 of 736 patients in the REGEN-COV 1200-mg group (1.0%) and in 24 of 748 patients in the placebo group who underwent randomization concurrently (3.2%) (relative risk reduction, 70.4%; P = 0.002). The median time to resolution of symptoms was 4 days shorter with each REGEN-COV dose than with placebo (10 days vs. 14 days; P<0.001 for both comparisons). REGEN-COV was efficacious across various subgroups, including patients who were SARS-CoV-2 serum antibody-positive at baseline. Both REGEN-COV doses reduced viral load faster than placebo; the least-squares mean difference in viral load from baseline through day 7 was −0.71 log 10 copies per milliliter (95% confidence interval [CI], −0.90 to −0.53) in the 1200-mg group and −0.86 log 10 copies per milliliter (95% CI, −1.00 to −0.72) in the 2400-mg group. Serious adverse events occurred more frequently in the placebo group (4.0%) than in the 1200-mg group (1.1%) and the 2400-mg group (1.3%); infusion-related reactions of grade 2 or higher occurred in less than 0.3% of the patients in all groups. CONCLUSIONS REGEN-COV reduced the risk of Covid-19-related hospitalization or death from any cause, and it resolved symptoms and reduced the SARS-CoV-2 viral load more rapidly than placebo. (Funded by Regeneron Pharmaceuticals and others; ClinicalTrials .gov number, NCT04425629.
Disclosure forms provided by the authors are available with the full text of this article at A data sharing statement provided by the authors is available with the full text of this article at We thank the trial participants; their families; the investigational site members involved in this trial (principal and subprincipal investigators, listed in the Supplementary Appendix); the Regeneron trial team (members listed in the Supplementary Appendix); the members of the independent data and safety monitoring committee; Brian Head, Ph.D., Caryn Trbovic, Ph.D., and S. Balachandra Dass, Ph.D., of Regeneron Pharmaceuticals for assistance with development of an earlier version of the manuscript; and Prime for assistance with the formatting and copy editing of an earlier version of the manuscript. Appendix The authors' full names and academic degrees are as follows: David M. Weinreich
Baum, Ajithdoss, Copin, REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters, Science
Baum, Fulton, Wloga, Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies, Science
Challen, Brooks-Pollock, Read, Dyson, Tsaneva-Atanasova et al., Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study, BMJ
Copin, Baum, Wloga, The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies, Cell
Davies, Abbott, Barnard, Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England, Science
Del Rio, Collins, Malani, Longterm health consequences of COVID-19, JAMA
Farrington, Manning, Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk, Stat Med
Hansen, Baum, Pascal, Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail, Science
Logue, Franko, Mcculloch, Sequelae in adults at 6 months after COVID-19 infection, JAMA Netw Open
Nalbandian, Sehgal, Gupta, Post-acute COVID-19 syndrome, Nat Med
Onder, Rezza, Brusaferro, Casefatality rate and characteristics of patients dying in relation to COVID-19 in Italy, JAMA
Rofail, Mcgale, Im, Development and content validation of the Symptoms Evolution of COVID-19: a patient-reported electronic daily diary in clinical and real-world studies, doi:10.1101/2021.07.06.21259654v1
Stokes, Zambrano, Anderson, Coronavirus disease 2019 case surveillance -United States, January 22, MMWR Morb Mortal Wkly Rep
Wang, Nair, Liu, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7, Nature
Weinreich, Sivapalasingam, Norton, REGEN-COV antibody cocktail in outpatients with Covid-19, doi:10.1101/2021.06.09.21257915v1
Weinreich, Sivapalasingam, Norton, REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med
Williamson, Walker, Bhaskaran, Factors associated with COVID-19-related death using OpenSAFELY, Nature
Wu, Mcgoogan, Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA
Xie, Liu, Liu, Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccineelicited sera, Nat Med
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop